» Articles » PMID: 30185579

Electronic Healthcare Databases in Europe: Descriptive Analysis of Characteristics and Potential for Use in Medicines Regulation

Overview
Journal BMJ Open
Specialty General Medicine
Date 2018 Sep 7
PMID 30185579
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Electronic healthcare databases (EHDs) are useful tools for drug development and safety evaluation but their heterogeneity of structure, validity and access across Europe complicates the conduct of multidatabase studies. In this paper, we provide insight into available EHDs to support regulatory decisions on medicines.

Methods: EHDs were identified from publicly available information from the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance resources database, textbooks and web-based searches. Databases were selected using criteria related to accessibility, longitudinal dimension, recording of exposure and outcomes, and generalisability. Extracted information was verified with the database owners.

Results: A total of 34 EHDs were selected after applying key criteria relevant for regulatory purposes. The most represented regions were Northern, Central and Western Europe. The most frequent types of data source were electronic medical records (44.1%) and record linkage systems (29.4%). The median number of patients registered in the 34 data sources was 5 million (range 0.07-15 million) while the median time covered by a database was 18.5 years. Paediatric patients were included in 32 databases (94%). Completeness of information on drug exposure was variable. Published validation studies were found for only 17 databases (50%). Some level of access exists for 25 databases (73.5%), and 23 databases (67.6%) can be linked through a personal identification number to other databases with parent-child linkage possible in 7 (21%) databases. Eight databases (23.5%) were already transformed or were in the process of being transformed into a common data model that could facilitate multidatabase studies.

Conclusion: A Few European databases meet minimal regulatory requirements and are readily available to be used in a regulatory context. Accessibility and validity information of the included information needs to be improved. This study confirmed the fragmentation, heterogeneity and lack of transparency existing in many European EHDs.

Citing Articles

INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Standardized Observational Data Sources for Real World Evidence on Medicine and Vaccine Safety.

Hoxhaj V, Andaur Navarro C, Riera-Arnau J, Elbers R, Alsina E, Dodd C Pharmacoepidemiol Drug Saf. 2025; 34(1):e70089.

PMID: 39805807 PMC: 11730612. DOI: 10.1002/pds.70089.


Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review.

Ahn S Diagnostics (Basel). 2024; 14(14).

PMID: 39061705 PMC: 11276298. DOI: 10.3390/diagnostics14141568.


Overview of global real-world data sources for pediatric pharmacoepidemiologic research.

Wharton G, Becker C, Bennett D, Burcu M, Bushnell G, Ferrajolo C Pharmacoepidemiol Drug Saf. 2023; 33(1):e5695.

PMID: 37690792 PMC: 10840986. DOI: 10.1002/pds.5695.


Development of Indirect Health Data Linkage on Health Product Use and Care Trajectories in France: Systematic Review.

Ranchon F, Chanoine S, Lambert-Lacroix S, Bosson J, Moreau-Gaudry A, Bedouch P J Med Internet Res. 2023; 25:e41048.

PMID: 37200084 PMC: 10236279. DOI: 10.2196/41048.


[BeoNet-Halle-development of a multifunctional database for the automated extraction of healthcare data from general practitioner and specialist practices].

Moser K, Mikolajczyk R, Bauer A, Tiller D, Christoph J, Purschke O Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023; 66(5):569-577.

PMID: 37079066 PMC: 10163113. DOI: 10.1007/s00103-023-03691-7.


References
1.
Burton P, Banner N, Elliot M, Knoppers B, Banks J . Policies and strategies to facilitate secondary use of research data in the health sciences. Int J Epidemiol. 2017; 46(6):1729-1733. PMC: 5837447. DOI: 10.1093/ije/dyx195. View

2.
Roberto G, Leal I, Sattar N, Loomis A, Avillach P, Egger P . Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. PLoS One. 2016; 11(8):e0160648. PMC: 5006970. DOI: 10.1371/journal.pone.0160648. View

3.
Mazzaglia G, Straus S, Arlett P, da Silva D, Janssen H, Raine J . Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs. Drug Saf. 2017; 41(2):191-202. PMC: 5808048. DOI: 10.1007/s40264-017-0604-4. View

4.
Trifiro G, Coloma P, Rijnbeek P, Romio S, Mosseveld B, Weibel D . Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?. J Intern Med. 2014; 275(6):551-61. DOI: 10.1111/joim.12159. View

5.
Engel P, Almas M, De Bruin M, Starzyk K, Blackburn S, Dreyer N . Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol. 2016; 83(4):884-893. PMC: 5346857. DOI: 10.1111/bcp.13165. View